1-11 of 11
Monica Mita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Gerald Falchook, Seth Rosen, Patricia LoRusso, Justin Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan Cassaday, Wael Harb, Julio Peguero, David C. Smith, Sarina A. Piha-Paul, Russ Szmulewitz, Marcus S. Noel, Swamy Yeleswaram, Phillip Liu, Julie Switzky, Gongfu Zhou, Fred Zheng, Amitkumar Mehta
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1247–1257.
https://doi.org/10.1158/1078-0432.CCR-18-4071
Published: 13 March 2020
View article titled, Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Open the PDF for Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors

Muhammad Wasif Saif, Chris Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario Castro, Susan O'Brien, Christopher Stogard, Daniel Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 445–455.
https://doi.org/10.1158/1078-0432.CCR-13-1257
Published: 16 January 2014
View article titled, A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Open the PDF for A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez-Ibarra, Hong Lu, Stuart Bailey, Sandra Chica, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3671–3680.
https://doi.org/10.1158/1078-0432.CCR-12-3404
Published: 30 June 2013
View article titled, First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Anthony W. Tolcher, Christopher J. Sweeney, Kyri Papadopoulos, Amita Patnaik, Elena G. Chiorean, Alain C. Mita, Kamalesh Sankhala, Eric Furfine, Jochem Gokemeijer, Lisa Iacono, Cheryl Eaton, Bruce A. Silver, Monica Mita
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 363–371.
https://doi.org/10.1158/1078-0432.CCR-10-1411
Published: 16 January 2011
View article titled, Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Open the PDF for Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin in another window
Includes: Supplementary data
Journal Articles

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Monica Mita, Kevin R. Kelly, Alain Mita, Alejandro D. Ricart, Ofelia Romero, Anthony Tolcher, Laurel Hook, Chukwuemeka Okereke, Ilya Krivelevich, Daniel P. Rossignol, Francis J. Giles, Eric K. Rowinsky, Chris Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 193–200.
https://doi.org/10.1158/1078-0432.CCR-10-0010
Published: 04 January 2011
View article titled, Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
Open the PDF for Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies in another window
Journal Articles

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Alain C. Mita, Chris H. Takimoto, Monica Mita, Anthony Tolcher, Kamalesh Sankhala, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu-Nien Sun, Z. Don Zhong, Michael B. Bass, NgocDiep Le, Patricia LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3044–3056.
https://doi.org/10.1158/1078-0432.CCR-09-3368
Published: 31 May 2010
View article titled, Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Open the PDF for Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4207–4212.
https://doi.org/10.1158/1078-0432.CCR-08-2429
Published: 15 June 2009
View article titled, A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Manuel Hidalgo, Quincy Chu, Alain Mita, Monica Mita, Garry Schwartz, José Jimeno, Javier Gómez, Vicente Alfaro, Claudia Lebedinsky, Patrik Zintl, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3591–3599.
https://doi.org/10.1158/1078-0432.CCR-08-2889
Published: 18 May 2009
View article titled, Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6663–6673.
https://doi.org/10.1158/1078-0432.CCR-08-0376
Published: 16 October 2008
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors in another window
Journal Articles

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, Roxanne Williams-Truax, Monica Mita, Joachim Beck, Howard Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth Culver, Ricky W. Johnstone, H. Miles Prince
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-07-4262
Published: 15 July 2008
View article titled, Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Open the PDF for Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Pamela N. Munster, Carolyn D. Britten, Monica Mita, Karen Gelmon, Susan E. Minton, Stacy Moulder, Dennis J. Slamon, Feng Guo, Stephen P. Letrent, Louis Denis, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1238–1245.
https://doi.org/10.1158/1078-0432.CCR-06-1539
Published: 22 February 2007
View article titled, First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors
Open the PDF for First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors in another window